In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare, engages with three industry experts to unravel the opportunities and challenges that lie ahead.
In the first segment, Robert Allen, the leader behind engagement and channel planning for U.S. Oncology at Bristol Myers Squibb, shares his insights into strategic planning for customer engagement and channel strategies. Next, Terry Terifay, the Chief Commercial Officer at Azurity Pharmaceuticals, offers a glimpse into what the future holds for the industry. In the third segment, Dorothy Gemmel, the Chief Commercial Officer of GoodRx, shares the projects she's excited about and her biggest piece of advice for others in the industry."
To learn more about the topics in this episode:
Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will
Providers can now see patients' insurance coverage in GoodRx's cost comparison tool
Bristol Myers banks on 25-plus label expansions to help weather IRA, Revlimid generics and more
GoodRx, Walgreens team to lower prices for 200 drugs
Fierce Pharma unveils the winners of the 5th annual creativity contest for outstanding marketing campaigns
See omnystudio.com/listener for privacy information.
A cell therapy reckoning
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development
[Sponsored] Unlocking health equity: The promise of digital health technologies
Advancements in cell & gene therapy manufacturing (Part II)
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
A look at pharma revenue rankings
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
The top money raisers in biotech
A closer look at European biotech investment in 2024
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Børsen Morgenbriefing
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast